Abstract: A removable lock core for use with a lock device having a locked state and an unlocked state is disclosed. The removeable lock core may include a cam member tailpiece which is moveable between a first position relative to a lock core body which corresponds to the lock device being in the locked state and a second position relative to a lock core body which permits removal of the removeable lock core from the lock device which corresponds to the lock device being in the unlocked state. The removeable lock core may include an electro-mechanical drive assembly which in a disengaged state is decoupled from the cam member tailpiece and in an engaged state is coupled to the cam member tailpiece. A cam lock having a locked state and an unlocked state for use with a catch is disclosed.

Abstract: The present disclosure describes systems and methods for providing enhanced location analysis and consumer insights using mobile sightings data. An approximate geographic location is useful to mobile service providers and advertisers who wish to provide targeted content to consumers based on their location. The location analysis described herein provides more depth and detail about the detected geographic location of the consumer and also insights into business locations visited by the user of the device, consumer/market segments and patterns of behavior (for an individual consumer and/or for aggregated group of consumers), retail trends and patterns, and other profile information. For example, a location profile analytics system as described herein can determine a probability that an approximate geographic location actually corresponds to a specific geographic location, such as a business location.

Abstract: The present disclosure describes systems and methods for providing enhanced location analysis and consumer insights using mobile sightings data. An approximate geographic location is useful to mobile service providers and advertisers who wish to provide targeted content to consumers based on their location. The location analysis described herein provides more depth and detail about the detected geographic location of the consumer and also insights into business locations visited by the user of the device, consumer/market segments and patterns of behavior (for an individual consumer and/or for aggregated group of consumers), retail trends and patterns, and other profile information. For example, a location profile analytics system as described herein can determine a probability that an approximate geographic location actually corresponds to a specific geographic location, such as a business location.

Abstract: The present disclosure describes systems and methods for automatically rolling-up data associated with one or more geographic units, such as ZIP+4 codes, such that the rollup comprises a minimum number of households to protect anonymity and ensure compliance with privacy regulations, while preserving variance of the underlying data associated with the geographic regions. Data attributes may include demographic data, socio-economic data, lifestyle segmentation, psychographic data, behavioral data, credit data, and other data. The rollup process may involve identifying one or more geographic units with a number of households below a minimum or threshold amount, applying filters to find candidate geographic units for rollup, scoring candidate geographic units to select best pairings for rollup, and repeating until the rollup group has at least the minimum number of households. The process may make trades off between granularity (e.g.

Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: The present disclosure describes systems and methods for automatically rolling-up data associated with one or more geographic units, such as ZIP+4 codes, such that the rollup comprises a minimum number of households to protect anonymity and ensure compliance with privacy regulations, while preserving variance of the underlying data associated with the geographic regions. Data attributes may include demographic data, socio-economic data, lifestyle segmentation, psychographic data, behavioral data, credit data, and other data. The rollup process may involve identifying one or more geographic units with a number of households below a minimum or threshold amount, applying filters to find candidate geographic units for rollup, scoring candidate geographic units to select best pairings for rollup, and repeating until the rollup group has at least the minimum number of households. The process may make trades off between granularity (e.g.

Abstract: The present disclosure describes systems and methods for automatically rolling-up data associated with one or more geographic units, such as ZIP+4 codes, such that the rollup comprises a minimum number of households to protect anonymity and ensure compliance with privacy regulations, while preserving variance of the underlying data associated with the geographic regions. Data attributes may include demographic data, socio-economic data, lifestyle segmentation, psychographic data, behavioral data, credit data, and other data. The rollup process may involve identifying one or more geographic units with a number of households below a minimum or threshold amount, applying filters to find candidate geographic units for rollup, scoring candidate geographic units to select best pairings for rollup, and repeating until the rollup group has at least the minimum number of households. The process may make trades off between granularity (e.g.

Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Abstract: Compounds of formula (I): wherein: m and n represent 1 or 2, A represents a pyrrolyl group, X represents a C(O), S(O) or SO2 group, R1 and R2 represent an alkyl group or, together with the nitrogen atom carrying them, form a heterocyclic group, R3 and R4, together with the atoms carrying them, form a heterocyclic group, R5 represents a hydrogen atom or an alkyl group, R6 represents a hydrogen atom or a halogen atom. Medicinal products containing the same which are useful in treating cancer.

Abstract: Compounds of formula (I): wherein: m and n represent 1 or 2, A represents a pyrrolyl group, X represents a C(O), S(O) or SO2 group, R1 and R2 represent an alkyl group or, together with the nitrogen atom carrying them, form a heterocyclic group, R3 and R4, together with the atoms carrying them, form a heterocyclic group, R5 represents a hydrogen atom or an alkyl group, R6 represents a hydrogen atom or a halogen atom. Medicinal products containing the same which are useful in treating cancer.

Abstract: Use of a polypeptide selected from the group consisting of USP13, USP26, USP38, USP42 or USP46 as a screening tool for an agent for treating cancer.

Abstract: Compounds of formula (I): wherein: A represents a 5, 6 or 7-membered (hetero)aromatic or non-aromatic ring, Z1, Z2 and Z3 each independently of the others represents a CH group or a nitrogen atom, it being understood that at least one of these three groups is a nitrogen atom, X represents an alkylene chain as defined in the description, R2 represents an aryl or heteroaryl group, the group R1 represents a group of formula (II) as defined in the description Medicinal products containing the same which are useful in treating conditions involving a defect in apoptosis.

Abstract: The invention relates to a method of screening and identifying modulators of the protein interaction between new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type programmed cell death in those patients.

Abstract: The invention relates to a method of identifying modulators of programmed cell death, comprising an interaction between a motif of Beclin protein and an anti-apoptotic member of the family of Bcl-2 proteins and the detection of said interaction be means of fluorescence polarization. The modulators identified on the basis of said method are administered to cancer patients in order to induce apoptotic- and/or autophagic-type programmed cell death. The invention also relates to a motif of the Beclin protein which can interact with an anti-apoptic member of the family of Bcl-2 proteins and to the use thereof in order to induce programmed cell death in a cancer patient.

Abstract: Compounds of formula (I): wherein: m and n represent 1 or 2, A represents a pyrrolyl group, X represents a C(O), S(O) or SO2 group, R1 and R2 represent an alkyl group or, together with the nitrogen atom carrying them, form a heterocyclic group, R3 and R4, together with the atoms carrying them, form a heterocyclic group, R5 represents a hydrogen atom or an alkyl group, R6 represents a hydrogen atom or a halogen atom. Medicinal products containing the same which are useful in treating cancer.

Abstract: Compound of formula (I): wherein: R1, R2, R3, R4, R5, R80, R90, R81, R91, Alk, Alk?, X, X? and G are as defined in the description. Medicinal products containing the same which are useful in the treatment of cancer diseases.